<p><strong>Autolus Therapeutics plc</strong>（纳斯达克代码：AUTL）的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达到 28%。不幸的是，上个月的涨幅对过去一年的损失几乎没有帮助，股票仍然下跌了 29%。</p>
<p>尽管价格大幅反弹，Autolus Therapeutics 的市销率（&#34;P/S&#34;）为 8.5 倍，相较于美国生物技术行业，仍然可能看起来像是一个买入机会，因为大约一半的公司市销率超过 12.1 倍，甚至市销率超过 84 倍的情况也相当普遍。然而，我们需要更深入地研究，以确定降低的市销率是否有合理的依据。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 Autolus Therapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/562879769-ps-multiple-vs-industry-1-dark-2/1766238315638?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="650" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/562879769-ps-multiple-vs-industry-1-dark-2/1766238315638"/></p>
<p>纳斯达克 GS:AUTL 市销率与行业比较 2025 年 12 月 20 日</p>
<h3>Autolus Therapeutics 的表现如何</h3>
<p>Autolus Therapeutics 最近的表现确实不错，其收入增长超过了大多数其他公司。一个可能的原因是，市销率较低是因为投资者认为这种强劲的收入表现未来可能不那么令人印象深刻。如果不是这样，那么现有股东有理由对股价的未来走势感到相当乐观。</p>
<p>想要了解分析师对公司的全面预测吗？那么我们 <strong>免费的</strong>Autolus Therapeutics 报告将帮助您揭示未来的趋势。</p>
<h2>收入增长指标对低市销率的启示是什么？</h2>
<p>Autolus Therapeutics 的市销率对于一家预计仅能实现有限增长的公司来说是典型的，重要的是，其表现还不如行业。</p>
<p>回顾过去，我们看到公司在过去 12 个月的收入经历了快速增长。最近三年期间，收入也经历了惊人的整体增长，这得益于其出色的短期表现。因此，股东们对这些中期收入增长率感到非常满意。</p>
<p>展望未来，九位分析师预计未来三年将实现每年 97% 的增长。预计行业每年将实现 130% 的增长，因此该公司的收入结果将相对较弱。</p>
<p>根据这些信息，我们可以理解为什么 Autolus Therapeutics 的市销率低于行业水平。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
<h2>Autolus Therapeutics 的市销率对投资者意味着什么？</h2>
<p>尽管 Autolus Therapeutics 的股价最近有所上涨，但其市销率仍落后于大多数其他公司。通常情况下，我们会警惕在做出投资决策时过度解读市销率，尽管它可以揭示其他市场参与者对公司的看法。</p>
<p>正如我们所怀疑的，我们对 Autolus Therapeutics 分析师预测的审查显示，其较差的收入前景正在导致其低市销率。目前，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。在这种情况下，很难看到股价在短期内强劲上涨。</p>
<p>值得注意的是，我们发现了 <strong>Autolus Therapeutics 的 2 个警示信号</strong>，您需要考虑这些因素。</p>
<p>如果您对 Autolus Therapeutics 的业务实力 <strong>不确定</strong>，不妨探索我们互动式的股票列表，寻找一些您可能错过的基本面良好的公司。</p>
<p>国防与灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

AUTL

<p>Autolus Therapeutics plc（纳斯达克代码：AUTL）的股价最近上涨了 28%，但过去一年仍下跌了 29%。尽管股价上涨，其市销率（P/S）为 8.5 倍，低于生物技术行业的平均水平。公司的收入增长显著，但未来的增长预计将落后于行业，这导致了较低的市销率。投资者对未来收入的意外感到谨慎，这影响了该股强劲上涨的潜力</p>

<p><strong>Autolus Therapeutics plc</strong> (NASDAQ:AUTL) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 29% over that time.</p>
<div class="lb-trans"><p><strong>Autolus Therapeutics plc</strong>（纳斯达克代码：AUTL）的股票在经历了一段动荡期后，最近一个月表现非常出色，涨幅达到 28%。不幸的是，上个月的涨幅对过去一年的损失几乎没有帮助，股票仍然下跌了 29%。</p>
</div><p>In spite of the firm bounce in price, Autolus Therapeutics' price-to-sales (or &#34;P/S&#34;) ratio of 8.5x might still make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 12.1x and even P/S above 84x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>尽管价格大幅反弹，Autolus Therapeutics 的市销率（&#34;P/S&#34;）为 8.5 倍，相较于美国生物技术行业，仍然可能看起来像是一个买入机会，因为大约一半的公司市销率超过 12.1 倍，甚至市销率超过 84 倍的情况也相当普遍。然而，我们需要更深入地研究，以确定降低的市销率是否有合理的依据。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>See our latest analysis for Autolus Therapeutics</p>
<div class="lb-trans"><p>查看我们对 Autolus Therapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/562879769-ps-multiple-vs-industry-1-dark-2/1766238315638" alt="" original-src="https://images.simplywall.st/asset/chart/562879769-ps-multiple-vs-industry-1-dark-2/1766238315638"/></p>
<p>NasdaqGS:AUTL Price to Sales Ratio vs Industry December 20th 2025</p>
<div class="lb-trans"><p>纳斯达克 GS:AUTL 市销率与行业比较 2025 年 12 月 20 日</p>
</div><h3>How Autolus Therapeutics Has Been Performing</h3>
<div class="lb-trans"><h3>Autolus Therapeutics 的表现如何</h3>
</div><p>Autolus Therapeutics certainly has been doing a good job lately as it's been growing revenue more than most other companies. One possibility is that the P/S ratio is low because investors think this strong revenue performance might be less impressive moving forward. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.</p>
<div class="lb-trans"><p>Autolus Therapeutics 最近的表现确实不错，其收入增长超过了大多数其他公司。一个可能的原因是，市销率较低是因为投资者认为这种强劲的收入表现未来可能不那么令人印象深刻。如果不是这样，那么现有股东有理由对股价的未来走势感到相当乐观。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on Autolus Therapeutics will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析师对公司的全面预测吗？那么我们 <strong>免费的</strong>Autolus Therapeutics 报告将帮助您揭示未来的趋势。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增长指标对低市销率的启示是什么？</h2>
</div><p>Autolus Therapeutics' P/S ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the industry.</p>
<div class="lb-trans"><p>Autolus Therapeutics 的市销率对于一家预计仅能实现有限增长的公司来说是典型的，重要的是，其表现还不如行业。</p>
</div><p>Taking a look back first, we see that the company's revenues underwent some rampant growth over the last 12 months. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. Accordingly, shareholders would have been over the moon with those medium-term rates of revenue growth.</p>
<div class="lb-trans"><p>回顾过去，我们看到公司在过去 12 个月的收入经历了快速增长。最近三年期间，收入也经历了惊人的整体增长，这得益于其出色的短期表现。因此，股东们对这些中期收入增长率感到非常满意。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 97% per annum as estimated by the nine analysts watching the company. With the industry predicted to deliver 130% growth per annum, the company is positioned for a weaker revenue result.</p>
<div class="lb-trans"><p>展望未来，九位分析师预计未来三年将实现每年 97% 的增长。预计行业每年将实现 130% 的增长，因此该公司的收入结果将相对较弱。</p>
</div><p>With this information, we can see why Autolus Therapeutics is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>根据这些信息，我们可以理解为什么 Autolus Therapeutics 的市销率低于行业水平。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
</div><h2>What Does Autolus Therapeutics' P/S Mean For Investors?</h2>
<div class="lb-trans"><h2>Autolus Therapeutics 的市销率对投资者意味着什么？</h2>
</div><p>Despite Autolus Therapeutics' share price climbing recently, its P/S still lags most other companies. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>尽管 Autolus Therapeutics 的股价最近有所上涨，但其市销率仍落后于大多数其他公司。通常情况下，我们会警惕在做出投资决策时过度解读市销率，尽管它可以揭示其他市场参与者对公司的看法。</p>
</div><p>As we suspected, our examination of Autolus Therapeutics' analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>正如我们所怀疑的，我们对 Autolus Therapeutics 分析师预测的审查显示，其较差的收入前景正在导致其低市销率。目前，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。在这种情况下，很难看到股价在短期内强劲上涨。</p>
</div><p>It is also worth noting that we have found <strong>2 warning signs for Autolus Therapeutics</strong> that you need to take into consideration.</p>
<div class="lb-trans"><p>值得注意的是，我们发现了 <strong>Autolus Therapeutics 的 2 个警示信号</strong>，您需要考虑这些因素。</p>
</div><p>If you're <strong>unsure about the strength of Autolus Therapeutics' business</strong>, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.</p>
<div class="lb-trans"><p>如果您对 Autolus Therapeutics 的业务实力 <strong>不确定</strong>，不妨探索我们互动式的股票列表，寻找一些您可能错过的基本面良好的公司。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防与灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

Autolus Therapeutics plc（NASDAQ:AUTL）的股价上涨了 28%，然而其业务表现仍然落后于行业平均水平